Frederik A Verburg1,2, David Pfister3, Axel Heidenreich3, Andreas Vogg4, Natascha I Drude4, Stefan Vöö5, Felix M Mottaghy4,5, Florian F Behrendt4. 1. Department of Nuclear Medicine, RWTH University Hospital Aachen, Pauwelsstraße 30, 52074, Aachen, Germany. fverburg@ukaachen.de. 2. Department of Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands. fverburg@ukaachen.de. 3. Department of Urology, RWTH University Hospital Aachen, Pauwelsstraße 30, 52074, Aachen, Germany. 4. Department of Nuclear Medicine, RWTH University Hospital Aachen, Pauwelsstraße 30, 52074, Aachen, Germany. 5. Department of Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
Abstract
PURPOSE: To examine the relationship between the extent of disease determined by [(68)Ga]PSMA-HBED-CC-PET/CT and the important clinical measures prostate-specific antigen (PSA), PSA doubling time (PSAdt) and Gleason score. METHODS: We retrospectively studied the first 155 patients with recurrent prostate cancer (PCA) referred to our university hospital for [(68)Ga]PSMA-HBED-CC PET/CT. RESULTS: PET/CT was positive in 44%, 79% and 89% of patients with PSA levels of ≤1, 1-2 and ≥2 ng/ml, respectively. Patients with high PSA levels showed higher rates of local prostate tumours (p < 0.001), and extrapelvic lymph node (p = 0.037) and bone metastases (p = 0.013). A shorter PSAdt was significantly associated with pelvic lymph node (p = 0.026), extrapelvic lymph node (p = 0.001), bone (p < 0.001) and visceral (p = 0.041) metastases. A high Gleason score was associated with more frequent pelvic lymph node metastases (p = 0.039). In multivariate analysis, both PSA and PSAdt were independent determinants of scan positivity and of extrapelvic lymph node metastases. PSAdt was the only independent marker of bone metastases (p = 0.001). Of 20 patients with a PSAdt <6 months and a PSA ≥2 ng/ml, 19 (95%) had a positive scan and 12 (60%) had M1a disease. Of 14 patients with PSA <1 ng/ml and PSAdt >6 months, only 5 (36%) had a positive scan and 1 (7%) had M1a disease. CONCLUSION: [(68)Ga]PSMA-HBED-CC PET/CT will identify PCA lesions even in patients with very low PSA levels. Higher PSA levels and shorter PSAdt are independently associated with scan positivity and extrapelvic metastases, and can be used for patient selection for [(68)Ga]PSMA-HBED-CC PET/CT.
PURPOSE: To examine the relationship between the extent of disease determined by [(68)Ga]PSMA-HBED-CC-PET/CT and the important clinical measures prostate-specific antigen (PSA), PSA doubling time (PSAdt) and Gleason score. METHODS: We retrospectively studied the first 155 patients with recurrent prostate cancer (PCA) referred to our university hospital for [(68)Ga]PSMA-HBED-CC PET/CT. RESULTS: PET/CT was positive in 44%, 79% and 89% of patients with PSA levels of ≤1, 1-2 and ≥2 ng/ml, respectively. Patients with high PSA levels showed higher rates of local prostate tumours (p < 0.001), and extrapelvic lymph node (p = 0.037) and bone metastases (p = 0.013). A shorter PSAdt was significantly associated with pelvic lymph node (p = 0.026), extrapelvic lymph node (p = 0.001), bone (p < 0.001) and visceral (p = 0.041) metastases. A high Gleason score was associated with more frequent pelvic lymph node metastases (p = 0.039). In multivariate analysis, both PSA and PSAdt were independent determinants of scan positivity and of extrapelvic lymph node metastases. PSAdt was the only independent marker of bone metastases (p = 0.001). Of 20 patients with a PSAdt <6 months and a PSA ≥2 ng/ml, 19 (95%) had a positive scan and 12 (60%) had M1a disease. Of 14 patients with PSA <1 ng/ml and PSAdt >6 months, only 5 (36%) had a positive scan and 1 (7%) had M1a disease. CONCLUSION: [(68)Ga]PSMA-HBED-CC PET/CT will identify PCA lesions even in patients with very low PSA levels. Higher PSA levels and shorter PSAdt are independently associated with scan positivity and extrapelvic metastases, and can be used for patient selection for [(68)Ga]PSMA-HBED-CC PET/CT.
Authors: Sebastian Mannweiler; Peter Amersdorfer; Slave Trajanoski; Jonathan A Terrett; David King; Gabor Mehes Journal: Pathol Oncol Res Date: 2008-09-18 Impact factor: 3.201
Authors: Francesco Ceci; Christian Uprimny; Bernhard Nilica; Llanos Geraldo; Dorota Kendler; Alexander Kroiss; Jasmin Bektic; Wolfgang Horninger; Peter Lukas; Clemens Decristoforo; Paolo Castellucci; Stefano Fanti; Irene J Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2015-05-15 Impact factor: 9.236
Authors: Clemens Kratochwil; Frederik L Giesel; Matthias Eder; Ali Afshar-Oromieh; Martina Benešová; Walter Mier; Klaus Kopka; Uwe Haberkorn Journal: Eur J Nucl Med Mol Imaging Date: 2015-01-09 Impact factor: 9.236
Authors: Shawn M Hillier; Kevin P Maresca; Genliang Lu; Ross D Merkin; John C Marquis; Craig N Zimmerman; William C Eckelman; John L Joyal; John W Babich Journal: J Nucl Med Date: 2013-06-03 Impact factor: 10.057
Authors: A Afshar-Oromieh; A Malcher; M Eder; M Eisenhut; H G Linhart; B A Hadaschik; T Holland-Letz; F L Giesel; C Kratochwil; S Haufe; U Haberkorn; C M Zechmann Journal: Eur J Nucl Med Mol Imaging Date: 2012-11-24 Impact factor: 9.236
Authors: C Marchal; M Redondo; M Padilla; J Caballero; I Rodrigo; J García; J Quian; D G Boswick Journal: Histol Histopathol Date: 2004-07 Impact factor: 2.303
Authors: Thomas A Hope; Jeremy Z Goodman; Isabel E Allen; Jeremie Calais; Wolfgang P Fendler; Peter R Carroll Journal: J Nucl Med Date: 2018-12-07 Impact factor: 10.057
Authors: Thomas Krohn; Anita Birmes; Oliver H Winz; Natascha I Drude; Felix M Mottaghy; Florian F Behrendt; Frederik A Verburg Journal: Eur J Nucl Med Mol Imaging Date: 2016-11-29 Impact factor: 9.236
Authors: Wolfgang P Fendler; Matthias Eiber; Mohsen Beheshti; Jamshed Bomanji; Francesco Ceci; Steven Cho; Frederik Giesel; Uwe Haberkorn; Thomas A Hope; Klaus Kopka; Bernd J Krause; Felix M Mottaghy; Heiko Schöder; John Sunderland; Simon Wan; Hans-Jürgen Wester; Stefano Fanti; Ken Herrmann Journal: Eur J Nucl Med Mol Imaging Date: 2017-06 Impact factor: 9.236
Authors: M Schostak; F König; M Bögemann; P Goebell; P Hammerer; S Machtens; C Schwentner; C Thomas; G von Amsberg; F-C von Rundstedt; A Heidenreich Journal: Urologe A Date: 2018-07 Impact factor: 0.639
Authors: Simona Malaspina; Ugo De Giorgi; Jukka Kemppainen; Angelo Del Sole; Giovanni Paganelli Journal: Radiol Med Date: 2018-08-16 Impact factor: 3.469